Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hematologic Malignancy Reports
Published in: Current Hematologic Malignancy Reports 5/2017

01-10-2017 | Myelodysplastic Syndromes (M Savona, Section Editor)

Nuances of Morphology in Myelodysplastic Diseases in the Age of Molecular Diagnostics

Authors: Aaron C. Shaver, Adam C. Seegmiller

Published in: Current Hematologic Malignancy Reports | Issue 5/2017

Login to get access

Abstract

Morphologic dysplasia is an important factor in diagnosis of myelodysplastic syndrome (MDS). However, the role of dysplasia is changing as new molecular genetic and genomic technologies take a more prominent place in diagnosis. This review discusses the role of morphology in the diagnosis of MDS and its interactions with cytogenetic and molecular testing. Recent changes in diagnostic criteria have attempted to standardize approaches to morphologic diagnosis of MDS, recognizing significant inter-observer variability in assessment of dysplasia. Definitive correlates between cytogenetic/molecular and morphologic findings have been described in only a small set of cases. However, these genetic and morphologic tools do play a complementary role in the diagnosis of both MDS and other myeloid neoplasms. Diagnosis of MDS requires a multi-factorial approach, utilizing both traditional morphologic as well as newer molecular genetic techniques. Understanding these tools, and the interplay between them, is crucial in the modern diagnosis of myeloid neoplasms.
Literature
1.
2.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnich HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–99.CrossRefPubMed
3.
Matsuda A, Germing U, Jinnai M, Iwanaga M, Misumi M, Kuendgen A, et al. Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification. Leukemia. 2007;21:678–86. doi:10.​1038/​sj.​leu.​2404571.PubMed
4.
Orazi A. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases. Pathobiology. 2007;74:97–114. doi:10.​1159/​000101709.CrossRefPubMed
5.
Foucar K. Myelodysplastic syndromes. In: Foucar K, Reichard K, Czuchlewski D, editors. Bone marrow pathology. 3rd ed. Chicago: ASCP Press; 2010.
6.
• Della Porta MG, Travaglino E, Boveri E, Ponzoni M, Malcovati L, Papaemmanuil E, et al. Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes. Leukemia. 2015;29:66–75. doi:10.​1038/​leu.​2014.​161. A systematic review of morphologic data was performed from 1,150 patients with peripheral blood cytopenias to generate a morphologic score with high sensitivity and specificity for the diagnosis of MDS. There were statistical associations with particular gene mutations and clinical outcomes. CrossRefPubMed
7.
Brunning RD, Bennett JM, Flandrin G, Matutes E, Head D, Vardiman JW, et al. Myelodysplastic syndromes: introduction. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of Tumours: Tumours of Haematopoietic and lymphoid tissues. 3rd ed. Lyon: IARC Press; 2001.
8.
Brunning RD, Orazi A, Germing U, Le Beau MM, Porwit A, Baumann I, et al. Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008.
9.
Tricot G, De Wolf-Peeters C, Vlietinck R, Verwilghen RL. Bone marrow histology in myelodysplastic syndrome: prognostic value of abnormal localization of immature precursors in MDS. Br J Haematol. 1984;58:217–25.CrossRefPubMed
10.
Rios A, Canizo MC, Sanz MA, Vallespi T, Sanz G, Torrabadella M, et al. Bone marrow biopsy in myelodysplastic syndromes: morphological characteristics and contribution to the study of prognostic factors. Br J Haematol. 1990;75:26–33.CrossRefPubMed
11.
Kuriyama K, Tomonaga M, Matsuo T, Ginnai I, Ichimaru M. Diagnostic significance of detecting pseudo-Pelger-Huet anomalies and micromegakaryocytes in myelodysplastic syndrome. Br J Haematol. 1986;63:665–9.CrossRefPubMed
12.
Hast R, Nilsson I, Widell S, Ost A. Diagnostic significance of dysplastic features of peripheral blood polymorphs in myelodysplastic syndromes. Leuk Res. 1989;13:173–8.CrossRefPubMed
13.
Cunningham JM, Patnaik MM, Hammerschmidt DE, Vercellotti GM. Historical perspective and clinical implications of the Pelger-Huet cell. Am J Hematol. 2008;84:116–9. doi:10.​1002/​ajh.​21320.CrossRef
14.
15.
16.
17.
Feng G, Gale RP, Cui W, Cai W, Huang G, Xu Z, et al. A systematic classification of megakaryocytic dysplasia and its impact on prognosis for patients with myelodysplastic syndromes. Exp Hematolg Oncol. 2016;5:12–20. doi:10.​1186/​s40164-016-0041-6.CrossRef
18.
19.
Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res. 2007;31:727–36. doi:10.​1016/​j.​leukres.​2006.​11.​009.CrossRefPubMed
20.
21.
Font P, Loscertales J, Benavente C, Bermejo A, Callejas M, Garcia-Alonso L, et al. Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification. Ann Hematol. 2013;92:19–24. doi:10.​1007/​s00277-012-1565-4.CrossRefPubMed
22.
Font P, Loscertales J, Soto C, Ricard P, Novas CM, Martin-Clavero E, et al. Inter-observer variance in myelodysplastic syndromes with less than 5% bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2% blasts. Ann Hematol. 2015;94:565–73. doi:10.​1007/​s00277-014-2252-4.CrossRefPubMed
23.
24.
25.
de Swart L, Smith A, MacKenzie M, Symeonidis A, Neukirchen J, Mikulendova D, et al. Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance. Ann Hematol. 2017;96:1105–12. doi:10.​1007/​s00277-017-3009-7.CrossRefPubMedPubMedCentral
26.
27.
28.
29.
30.
31.
Sheikha A. Dyserythropoiesis in 105 patients with visceral leishmaniasis. Lab Hematol. 2004;10:206–11.PubMed
32.
Carpenter SL, Zimmerman SA, Ware RE. Acute parvovirus B19 infection mimicking congenital dyserythropoietic anemia. Pediatr Hematol Oncol. 2004;26:133–5.CrossRef
33.
Ryu T, Ikeda M, Okazaki Y, Tokuda H, Yoshino N, Honda M, et al. Myelodysplasia associated with acquired immune deficiency syndrome. Intern Med. 2001;40:795–801.CrossRefPubMed
34.
Kennedy GA, Kay TD, Johnson DW, Hawley CM, Campbell SB, Isbel NM, et al. Neutrophil dysplasia characterised by a pseudo-Pelger-Huet anomaly occurring with the use of mycophenolate mofetil and ganciclovir following renal transplantation: a report of five cases. Pathology. 2002;34:263–6. doi:10.​1080/​0031302022013136​.CrossRefPubMed
35.
36.
Taegtmeyer AB, Halil O, Bell AD, Carby M, Cummins D, Banner NR. Neutrophil dysplasia (acquired pseudo-Pelger-Huet anomaly) caused by ganciclovir. Transplantation. 2005;80:127–30.CrossRefPubMed
37.
38.
Schmitz LL, McClure JS, Litz CE, Dayton V, Weisdorf DJ, Parkin JL, et al. Morphologic and quantitative changes in blood and marrow cells following growth factor therapy. Am J Clin Pathol. 1994;101:67–75.CrossRefPubMed
39.
Westhoff DD, Samaha RJ, Barnes A. Arsenic intoxication as a cause of megaloblastic anemia. Blood. 1975;45:241–6.PubMed
40.
Pye KG, Kelsey SM, House IM, Newland AC. Severe dyserythropoiesis and autoimmune thrombocytopenia associated with ingestion of kelp supplements. Lancet. 1992;339:1540.CrossRefPubMed
41.
Michot F, Gut J. Alcohol-induced bone marrow damage: a bone marrow study in alcohol-dependent individuals. Acta Haematol. 1987;78:252–7.CrossRefPubMed
42.
43.
44.
45.
46.
47.
48.
Valent P, Bain BJ, Bennett JM, Wimazal F, Sperr WR, Mufti G, et al. Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS. Leuk Res. 2012;36:1–5. doi:10.​1016/​j.​leukres.​2011.​08.​016.PubMed
49.
Valent P, Jager E, Mitterbauer-Hohendanner G, Mullauer L, Schwarzinger I, Sperr WR, et al. Idiopathic bone marrow dysplasia of unknown significance (IDUS): definition, pathogenesis, follow up, and prognosis. Am J Cancer Res. 2011;1:531–41.PubMed
50.
• Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126:9–16. doi:10.​1182/​blood-2015-03-631747. A comprehensive review of the new concept of clonal hematopoiesis of interminate potential (CHIP), and the diagnostic and clinical differences between this entity and idiopathic cytopenias of undetermined significance (ICUS), clonal cytopenias of undetermined significance (CCUS), and MDS. CrossRefPubMedPubMedCentral
51.
Cantu Rajnoldi A, Fenu S, Kerndrup G, van Wering ER, Niemeyer CM, Baumann I. Evaluation of dysplastic features in myelodysplastic syndromes: experience from the morphology group of the European working group of MDS in childhood (EWOG-MDS). Ann Hematol. 2005;84:429–33. doi:10.​1007/​s00277-005-1034-4.CrossRefPubMed
52.
•• Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405. doi:10.​1182/​blood-2016-03-643544. This review comprehensively discusses the changes in diagnostic criteria of myeloid neoplasms and acute leukemia in the 2016 revision to the World Health Organization classification of hematolymphoid malignancies, and how they should be applied in practice. CrossRefPubMed
53.
Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluation prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–88.PubMed
54.
Schanz J, Tuchler H, Sole F, Mallo M, Luno E, Cervera J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international databased merge. J Clin Oncol. 2012;30:820–9. doi:10.​1200/​JCO.​2011.​35.​6394.CrossRefPubMedPubMedCentral
55.
56.
Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110:4385–95. doi:10.​1182/​blood-2007-03-082404.CrossRefPubMed
57.
Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JJ, Sokai G. Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature. 1974;251:437–8.CrossRefPubMed
58.
59.
60.
Kurtin PJ, Dewald GW, Shields DJ, Hanson CA. Hematologic disorders associated with deletions of chromosome 20q: a clinicopathologic study of 107 patients. Am J Clin Pathol. 1996;106:680–8.CrossRefPubMed
61.
62.
Jawad MD, Shi M, Oliveira JL, Hoyer JD, Hook CC, Go RS. Clinical course of patient with incidental finding of 20q- in the bone marrow without a morphologic evidence of myeloid neoplasm. Am J Hematol. 2016;91:556–9. doi:10.​1002/​ajh.​24347.CrossRefPubMed
63.
Courville EL, Singh C, Yohe S, Linden MA, Naemi K, Berger M, et al. Patients with a history of chemotherapy and isolated del(20q) with minimal myelodysplasia have an indolent course. Am J Clin Pathol. 2016;145:459–66. doi:10.​1093/​ajcp/​aqw024.CrossRefPubMed
64.
65.
66.
•• Malcovati L, Karimi M, Papaemmanuil E, Ambaglio I, Jadersten M, Jansson M, et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood. 2015;126:233–41. doi:10.​1182/​blood-2015-03-633537. This study shows the high prevalence of SF3B1 mutations in bone marrows from patients with myeloid neoplasms that contain ring sideroblasts. It demonstrates that these mutations are associated with lower rates of disease progression and improved overall survival. CrossRefPubMedPubMedCentral
67.
Patnaik MM, Hanson CA, Sulai NH, Hodnefield JM, Knudson RA, Ketterling RP, et al. Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts. Blood. 2012;119:5674–7. doi:10.​1182/​blood-2012-03-415356.CrossRefPubMed
68.
•• Malcovati L, Papaemmanuil E, Ambaglio I, Elena C, Galli A, Della Porta MG, et al. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Blood. 2014;124:1513–21. doi:10.​1182/​blood-2014-03-560227. This is a large study of genotype/phenotype relationships in 308 patients with myeloid malignancies. It shows that cases carrying SF3B1 mutations form a distinct clinicopathologic entity. Other driver mutations are associated with multilineage dysplasia and monocytosis. CrossRefPubMedPubMedCentral
69.
70.
Patel BJ, Przychodzen B, Thota S, Radivoyevitch T, Visconte V, Duzmanovic T, et al. Genomic determinants of chronic myelomonocytic leukemia. Leukemia. 2017; doi:10.​1038/​leu.​2017.​164.
71.
Haferlach T, Bennett JM, Loffler H, Gassmann W, Andersen JW, Tuzuner N, et al. Acute myeloid leukemia with translocation (8;21). Cytomorphology, dysplasia, and prognostic factors in 41 cases. Leuk Lymphoma. 1996;23:227–34. doi:10.​3109/​1042819960905482​5.CrossRefPubMed
72.
73.
• Jeromin S, Haferlach T, Weissmann S, Meggendorfer M, Eder C, Nadarajah N, et al. Refractory anemia with ring sideroblasts and marked thrombocytosis (RARS-T) cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2 V617F and ASXL1 mutations. Haematologica. 2015;100:e125–7. doi:10.​3324/​haematol.​2014.​119032. This study showed the consistent presence of mutations in SF3B1 and other spliceosome genes along with JAK2 and ASXL1 mutations in patients with MDS/MPN-RS-T. This combination of mutations could define this new category of neoplasm as a distinct biologic entity. CrossRefPubMedPubMedCentral
74.
Broseus J, Lippert E, Harutyunyan AS, Jeromin S, Zipperer E, Florensa L, et al. Low rate of calreticulin mutations in refrectory anemia with ring sideroblasts and marked thrombocytosis. Leukemia. 2014;28:1374–6. doi:10.​1038/​leu.​2014.​49.CrossRefPubMed
75.
Boiocchi L, Espinal-Witter R, Geyer JT, Steinhilber J, Bonzheim I, Knowles DM, et al. Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease. Mod Pathol. 2013;26:204–12. doi:10.​1038/​modpathol.​2012.​165.CrossRefPubMed
76.
77.
Metadata
Title
Nuances of Morphology in Myelodysplastic Diseases in the Age of Molecular Diagnostics
Authors
Aaron C. Shaver
Adam C. Seegmiller
Publication date
01-10-2017
Publisher
Springer US
Published in
Current Hematologic Malignancy Reports / Issue 5/2017
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-017-0405-y

Other articles of this Issue 5/2017

Current Hematologic Malignancy Reports 5/2017 Go to the issue

Chronic Myeloid Leukemias (J Pinilla-Ibarz, Section Editor)

Minimal Residual Disease Eradication in CML: Does It Really Matter?

Myeloproliferative Neoplasms (B Stein, Section Editor)

Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: a Review of the Recent Literature

Myeloproliferative Neoplasms (B Stein, Section Editor)

Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia

Myeloproliferative Neoplasms (B Stein, Section Editor)

Contemporary Use of Interferon Therapy in the Myeloproliferative Neoplasms

CART and Immunotherapy (M Ruella, Section Editor)

Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies

Myelodysplastic Syndromes (M Savona, Section Editor)

Patient-Reported Outcomes in Myelodysplastic Syndromes and MDS/MPN Overlap Syndromes: Stepping Onto the Stage with Changing Times
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits